Search

Displaying results 2561 - 2570 of 4238 in total
  1. Drug

    Methyprylon

    go.drugbank.com/drugs/DB01107
    ApprovedIllicitWithdrawn

    However, with the introduction of newer drugs with fewer side effects, such as benzodiazepines, the clinical use of methyprylon is now limited.

  2. Drug

    Apomorphine

    go.drugbank.com/drugs/DB00714
    ApprovedInvestigational

    [A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.

  3. Drug

    Amantadine

    go.drugbank.com/drugs/DB00915
    ApprovedInvestigational

    It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia.

  4. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 201...

  5. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment. … [L63806,L63934] Established ADHD pharmacotherapy acts on norepinephrine and dopamine without a serotonergic component, and Otsuka describes centanafadine as the first and only approved norepinephrine-dopamine-serotonin

  6. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

  7. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [L15153] The life cycle of head lice (_Pediculus capitis_) is approximately 30 days, seven to twelve of which are spent as eggs laid on hair shafts near the scalp. … [A216183] Topical pediculicides generally lack adequate ovicidal activity,[A216183] including standard-of-care treatments such as [permethrin], and many require a second administration 7-10 days following

  8. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment … remain asymptomatic, typical symptoms of MF arise from abnormalities in blood cell production and may therefore include various cytopenias, infections, splenomegaly, and general systemic symptoms such as

  9. Drug

    Arsenic trioxide

    go.drugbank.com/drugs/DB01169
    ApprovedInvestigational

    The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.

  10. Drug

    Xanthan gum

    go.drugbank.com/drugs/DB11253
    Approved

    It is used as a thickening agent and stabilizer in emulsions.